glp 1 parkinson's Repurposing GLP-1 Receptor Agonists for Disease: Current Evidence and Future Opportunities | Pharmaceutical Medicine Incretin and insulin signaling as

Generic manufacturers filed Paragraph IV challenges, and BMS settled with each of them, granting staggered entry dates starting in 2022 with volume caps that limited generic competition to a small fraction of the market for years

Obesity Drug Market Overview and Growth Potential The US obesity drug market is on a meteoric rise, projected to soar past USD 73 billion by 2034

These may include a GLP-1 agonist plus supporting ingredients like amino acids, B vitamins, and metabolic cofactors designed to work synergistically

The development of oral formulations, such as oral semaglutide, has been a notable advancement in improving treatment acceptance